Huadong Medicine Co., Ltd Secures Partnership and Commercial Rights for Yuyan’s Botulinum Toxin
China-based Huadong Medicine Co., Ltd (SHE: 000963) has entered into an equity investment and partnership...
SHE: 000963
Huadong Medicine’s Arcalyst (Rilonacept) Filing for CAPSs Accepted by China’s NMPA
Huadong Medicine Co., Ltd (SHE: 000963), a China-based pharmaceutical company, has announced that the National...
SanegeneBio Partners with Huadong Medicine to Develop RNAi Therapeutics for Metabolic Diseases
Suzhou-based RNA interference (RNAi) therapeutics developer SanegeneBio has entered into a partnership with compatriot firm...
Huadong Medicine’s Elahere Accepted for NMPA Review in China for Ovarian Cancer Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration...
Huadong Medicine Secures Global Licensing Agreement for ATGC-110 Botulinum Toxin A Injection
China-based Huadong Medicine Co., Ltd. (SHE: 000963) has announced a strategic licensing agreement with South...
Huadong Medicine’s Subsidiary Viora Ltd’s V20 Accepted for NMPA Review
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration...
Huadong Medicine Secures Exclusive Rights to MC2 Therapeutics’ Plaque Psoriasis Therapy in China
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced a licensing agreement with Denmark-headquartered MC2...
Huadong Medicine’s HDM3001, a Biosimilar to Stelara, Accepted for Review by NMPA
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration...
Huadong Medicine Secures Exclusive Rights to Arcutis’ Daxas in Greater China and South-East Asia
Huadong Medicine Co., Ltd (SHE: 000963) has announced a significant licensing agreement with Arcutis (NASDAQ:...
Shanghai Benemae’s Benaglutide Approved by NMPA for Adult Weight Management in China
The National Medical Products Administration (NMPA) has indicated on its website that benaglutide, developed by...
Huadong Medicine Receives NMPA Approval for Phase I Clinical Trial of DR10624 for Weight Management
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...
Huadong Medicine’s Elahere Receives Approval for FRα Positive Cancer Treatment in China
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving approval to introduce Elahere (mirvetuximab...
Huadong Medicine’s Liraglutide Biosimilar Gains NMPA Approval for Weight Loss Indication
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received additional indication...
Huadong Medicine’s Mirvetuximab Soravtansine Heads for Priority Review by China’s CDE
The China’s Center for Drug Evaluation (CDE) website has indicated that Huadong Medicine Co., Ltd...
Huadong Medicine Receives NMPA Approval for DR30206 Clinical Study in Advanced Solid Tumors
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...
Sanyou Biopharmaceuticals and Huadong Medicine Expand Partnership on Macromolecule Therapeutics
China-based Sanyou Biopharmaceuticals Co., Ltd has announced a licensing deal with compatriot firm Huadong Medicine...
Huadong Medicine’s Subsidiary Perfect mRNA Biotechnology Partners with Yoltech Therapeutics
China-based Huadong Medicine Co., Ltd (SHE: 000963) subsidiary, Hangzhou Perfect mRNA Biotechnology Co., Ltd, has...
Hybio Pharmaceutical’s Semaglutide API Receives FDA Review Acceptance
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced that the US Food and Drug...
Huadong Medicine’s HDM1002 Receives NMPA Approval for Type 2 Diabetes Clinical Trial
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving clinical trial approval from the...
Huadong Medicine’s HDM1002 Receives FDA Approval for Clinical Trials
Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has announced that it...